Abstract
Introduction
Hepatitis B is endemic in Lao PDR and about 9% of the adult population is chronically infected. In this study, we investigated regional, occupational, age and sex-related differences in hepatitis B epidemiology in Lao blood donors.
Methods
5017 voluntary blood donors from 8 different provinces were tested for hepatitis B markers by ELISA. Predictors for the prevalence of hepatitis B surface antigen (HBsAg) and antibodies against the core antigen (anti-HBc) were assessed by bivariate and multivariable analyses.
Results
In total, 41% of the participants were positive for anti-HBc; the HBsAg prevalence was estimated at 6.9% among all participants (9.2% among first-time donors and 3.9% among repeat donors). Among first-time donors, HBsAg positivity was associated independently with being male (p<0.001), being from the North (p<0.001) and being soldier (p<0.001). Participants were more likely to be anti-HBc positive when they were male (p<0.001), from the Northern provinces (p<0.001) and older than 20 years (p<0.01).
Conclusion
In conclusion, our study confirmed an overall high HBsAg and anti-HBc prevalence in Lao PDR, albeit with considerable regional variation. The identification of a sizeable number of HBsAg positives among repeat donors warrants a thorough investigation of current blood screening, record keeping, donor identification and counselling practises.
Introduction
Hepatitis B is a major public health problem worldwide. Chronic hepatitis B virus (HBV) infection causes severe liver damage and 25% of patients die later from related chronic active hepatitis, cirrhosis or primary hepatocellular carcinoma (HCC) [1–3]. Mother-to-child transmission is generally the most common transmission route in Southeast Asia. The risk of developing chronic hepatitis B is as high as 90% if infected at birth and decreases to 5–10% if infection occurs in adulthood [4,5]. Highly endemic countries have chronic HBV infection rates between 8–20%, e.g. parts of Southeast Asia, tropical Africa and parts of China [6–10]. In these regions, the burden of HBV-related HCC and hospitalization are dramatically high.
Hepatitis B vaccination was introduced in Lao PDR as a three-dose course in combination with Diphtheria-Tetanus-Pertussis in 2001. An additional birth dose followed in 2003 [11,12]. Since 2009, the pentavalent diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine (DTPw-HepB-Hib) has been used. In 2018, the estimated coverage for the 3rd dose of DTPw-HepB-Hib was 84% [13], while the birth dose coverage was only 55% [14].
More than 40% of the adult Lao population, born before introduction of the vaccine, are likely to have been exposed to the virus [12,15,16]. Despite representing a substantial public health burden, the epidemiology of hepatitis B in Lao PDR is not well understood. The lack of HBV surveillance and limited access to testing undermine efforts to assess HBV treatment and disease burden in the whole country. In recent years, studies investigated the prevalence of chronic infection among mothers and their children as well as protection levels due to vaccination [12,17–20].
In Lao PDR, more than 30,000 blood units are used for transfusion every year (Dr. Chantala Souksakhone, Director of National Blood Transfusion Center, personal communication, 2018). The high endemicity of HBV increases the relative risk of transfusion transmitted infection (TTI). The WHO recommends a mandatory pre-transfusion blood screening for HBV, Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Syphilis in all countries [21]. The routine screening for HBV infection was introduced by, the Lao National Blood Centre (NBC) in the early 1970s and includes the screening for the hepatitis B surface antigen (HBsAg) but not for the anti- hepatitis B core antibodies (anti-HBc) due to limited resources. Blood donors positive for HBsAg are informed of their HBV infection status, counselled and advised not to return for blood donation (Dr. Chantala Souksakhone, personal communication, 2018). However, due to challenges with donor compliance, counselling and maintenance of donor records, some HBsAg positive donors still return for blood donation. Furthermore, due to limited resources, the blood is currently screened only for HBsAg, but not for antibodies against HBV. Blood donors are not compensated for their donations.
In this study, we investigated a large cohort of Lao first time and repeat blood donors enrolled at eight different blood donation sites nationwide for markers of HBV infection in order to determine regional, occupational and age or sex related differences.
Methods
Participants
From November 2013 to May 2015, we recruited 5017 voluntary blood donors during routine blood donation visits for this study. Recruitment took place at 8 different blood centers: the NBC in Vientiane Capital in Central Lao PDR, Khammouane (KHM) and Attapeu (ATP) in the South, and Luang Prabang (LPB), Luang Namtha (LNT), Phongsaly (PSL), Huaphan (HPN) and Xaiyabuly (XAY) in the North (S1 Fig).
Blood donor eligibility was assessed according to the standards of the National Blood Transfusion Service and included history of blood donations. For donors less than 18 years old, the recommendation is to have school administrators to approve on behalf of the parents and to provide the telephone number of the parents to inform them and get verbal consent. The blood donors were informed about the study and enrolled after written informed consent. According to the regulations of the Lao ethics committee, people above 15 years of age are allowed to provide consent for study participation. The study, including the informed consent form, was approved by the Lao National Ethics Committee for Health Research (reference NECHR 059/2013 and 059/2014). All experiments were done in accordance with relevant regulations and guidelines.
Sample and data collection
5 ml blood were collected at the time of blood donation. Samples collected by either fixed or mobile units of NBC were shipped to Institut Pasteur du Laos (IPL) for serum separation, storage and subsequent laboratory testing. At the provincial level, the samples were processed at the study site. The serum was frozen at -20°C and shipped to IPL every three months. All serum samples were stored at -80°C at IPL until analysis. The demographic data of donors were collected, including age, sex and occupation, as well as number of donations, date and location of blood donation.
Laboratory analyses
Commercial ELISA kits (Diasorin, Italy) were used to detect anti-HBc and anti-HBs antibodies. Anti-HBc positive samples that were negative for anti-HBs antibodies or with unknown anti-HBs status, were tested for HBsAg (Diasorin, Italy). Anti-HBc negative samples were considered to be negative for HBsAg. For the purpose of this study, HBsAg positivity was interpreted as chronic infection. Anti-HBc positive results indicated previous exposure to the virus, whereas anti-HBs positive results were indicative of immune protection following infection (in the presence of anti-HBc antibodies) or vaccination (anti-HBs alone). According to the manufacturer’s instruction, a titer ≥ 10 IU/L was considered as reactive for anti-HBs. Samples with an OD value within the +/- 10% range of the OD value of the cut-off calibrator were considered as “equivocal” for anti-HBs.
Data analyses
Data analyses were conducted using R statistical software [22] with the following packages: tidyverse [23], MASS [24], car [25], lmtest [26] and epitools [27]. For first-time donors, bivariate and multivariable (logistic regression) analyses were performed in order to investigate associations with HBsAg or anti-HBc positive status. In bivariate analyses, odds ratio, 95% confidence intervals (CI) and p values were calculated for seropositive participants. Binary regressions were done with a stepwise method for removing variables not associated with the response variable one by one, considering the p-value of the variable as well as the Akaike Information Criterion (AIC) of the model. A p value <0.05 was considered statistically significant. A correlation was assumed if a correlation value of more than 0.5 or a variance inflation factor of more than 5 was obtained. The decision to exclude a variable was made on a case-by-case basis, with the variable considered as less important and/or with the lower impact being removed. The variables in the models were tested for potential interactions. The final model was compared with the null model using a likelihood ratio test (R function “Anova” with argument test set to “Chisq”). The individual effect of the variables was tested using Wald tests (R function “Anova” with argument test.statistics set to “Wald”).
Results
Participant characteristics
From the 5017 participants included, the majority were male (68.1%), students (68.3%) and younger than 25 years of age (80.3%, mean age = 22.2 years, ranging from 16 to 65 years) (S1 Table). Information regarding the frequency of blood donations was available for all but 5 participants. More than half of the 5012 participants were first-time donors (55.8%), 21.1% gave blood for the second time and all others more than two times (ranging from 3 to 35 times).
Serological profiles of HBV markers
Overall serological profiles
All 5017 samples were tested for anti-HBc antibodies and 2056 (41%) were positive (Table 1). Due to limited serum volume and financial constraints and because the focus of the study was on anti-HBc and HBsAg prevalence, only 3602 participants were in addition tested for the presence of anti-HBs antibodies. 20.3% were positive for anti-HBs and 73 (1.5%) participants had an equivocal result. Only 3.5% of all participants were anti-HBs positive and anti-HBc negative, indicating previous vaccination. 636 participants were anti-HBc positive and anti-HBs negative, and from those, 247 were HBsAg positive (4.9% of the total). For 533 anti-HBc positive participants, the anti-HBs status was unknown and 95 of them were HBsAg positive. Due to low volumes of the serum samples, 35 (3%) could not be tested for HBsAg (Table 1). Overall, 342 of the 1134 participants tested were positive for HBsAg. For this study, we considered all anti-HBc negative samples as well as anti-HBc positive and anti-HBs positive or equivocal samples as negative for HBsAg.
Table 1. Serological profiles of the participants.
Serological profiles (N = 5017) | n (%) | n HBsAg (+) | |
---|---|---|---|
anti-HBc (-) | anti-HBs (-) | 1874 (37.3) | |
anti-HBs (+) | 175 (3.5) | ||
anti-HBs (+/-) | 30 (0.6) | ||
anti-HBs status unknown | 882 (17.6) | ||
anti-HBc (+) | anti-HBs (-) | 636 (12.7) | 247/629† (39.3%) |
anti-HBs (+) | 844 (16.8) | ||
anti-HBs (+/-) | 43 (0.9) | ||
anti-HBs status unknown | 533 (10.6) | 95/505‡ (18.8%) |
Anti-HBc = anti-hepatitis B core antibody; anti-HBs = anti-hepatitis B surface antibody; HBsAg = hepatitis B surface antigen.
† Due to low volume, the serum of 7 participants could not be tested for HBsAg ‡ Due to low volume, the serum of 28 participants could not be tested for HBsAg.
Serological profiles by participant characteristics
The proportion of anti-HBc positives was higher in male donors, in participants ≥36 years and in participants from the Northern provinces (S2 Table). Male participants, donors from Northern provinces and soldiers showed a higher prevalence of chronic infection.
The prevalence of anti-HBc antibodies and HBsAg varied strongly by geographic location (Fig 1, S2 Table). Participants from provinces located in the North of Lao PDR seemed to be disproportionally affected by HBV infection with an anti-HBc seropositivity of 62.2% and HBsAg prevalence of 11.5% as compared to 27.1% and 5.0% in the South. The lowest rate of anti-HBc positivity was found in Khammouane province (25.5%) while the highest rate was observed in participants from Huaphan province (69.8%). The highest rate of chronic infection was observed in Luang Namtha (18.9%).
Serological profiles of first-time donors compared to repeat donors
From the 5012 participants with known numbers of blood donations, 55.8% were first-time donors. All 2799 first-time donors were tested for anti-HBc, but due to low sample volumes, only 2778 were tested for HBsAg. The overall anti-HBc prevalence was significantly higher in first-time donors than in repeat donors (44.1% vs. 37%; p<0.001). Anti-HBc seropositivity in first-time donors also varied by province (S3 Table). The prevalence of anti-HBc was higher in the Northern provinces compared to the other provinces irrespective of the age group.
Likewise, the prevalence of HBsAg was significantly higher in first-time donors than in repeat donors (9.2 vs. 3.9; p<0.001) and HBsAg prevalence varied by province (Fig 2). The prevalence of HBsAg in first-time donors was higher in the Northern provinces (13.1%) compared to Central and Southern provinces (6.6% and 5.6% respectively). The prevalence of HBsAg declined with increasing numbers of blood donations (Fig 3).
Factors associated with HBsAg positivity in first-time donors
After bivariate analysis, all variables were included in the logistic regression model to evaluate the relative contribution of each factor on being seropositive for HBsAg. Three variables remained independently associated with being seropositive for HBsAg. Male participants, soldiers and participants from Northern provinces were significantly more likely to be positive for HBsAg (Table 2).
Table 2. Risk factor analysis for HBsAg seroprevalence among first-time donors (N = 2778).
Variable | Bivariate analysis | Multivariable analysis | ||||||
---|---|---|---|---|---|---|---|---|
n HBsAg (+)/N total per group (%) | OR | 95% CI | P-value | OR | 95% CI | P-value | ||
Age (years) | ≤ 20 | 157/1849 (8.5) | Ref | |||||
21–25 | 53/480 (11.0) | 1.34 | [0.96–1.86] | 0.089 | NS | |||
26–30 | 27/222 (12.2) | 1.49 | [0.97–2.3] | 0.080 | ||||
31–35 | 10/95 (10.5) | 1.23 | [0.65–2.49] | 0.454 | ||||
≥ 36 | 9/132 (6.8) | 0.79 | [0.39–1.58] | 0.625 | ||||
Sex | Female | 44/929 (4.7) | Ref | |||||
Male | 212/1849 (11.5) | 2.6 | [1.86–3.64] | <0.001 | 2.23 | [1.6–3.19] | <0.001 | |
Occupation | Student | 162/1947 (8.3) | Ref | |||||
Office worker | 10/186 (5.4) | 0.63 | [0.32–1.21] | 0.200 | 0.82 | [0.39–1.53] | 0.560 | |
Soldier | 66/426 (15.5) | 2.02 | [1.48–2.75] | <0.001 | 1.65 | [1.18–2.3] | <0.001 | |
Other | 18/219 (8.2) | 0.99 | [0.59–1.64] | 1.000 | 0.7 | [0.4–1.15] | 0.180 | |
Region | Centre | 49/738 (6.6) | Ref | |||||
South | 45/801 (5.6) | 0.84 | [0.55–1.27] | 0.460 | 0.68 | [0.43–1.05] | 0.080 | |
North | 162/1239 (13.1) | 2.12 | [1.52–2.95] | <0.001 | 1.84 | [1.3–2.63] | <0.001 |
OR = odds ratio; CI = confidence interval.
Factors associated with anti-HBc positivity in first-time donors
In bivariate analysis, all four variables (sex, age, occupation and recruitment site) were significantly associated with anti-HBc positivity and therefore included in the logistic regression model (Table 3). All variables remained independently associated with being seropositive for anti-HBc. Male participants and participants from the North were 1.5 and 3.3 times more likely to be positive for anti-HBc compared to females and participants from Central provinces. In addition, participants over 20 years of age were more likely to test positive for anti-HBc. In contrast to factors associated with HBsAg positivity, soldiers were not more likely to have been previously exposed to HBV.
Table 3. Risk factor analysis for anti-HBc seroprevalence among first-time donors (N = 2799).
Variable | Bivariate analysis | Multivariable analysis | ||||||
---|---|---|---|---|---|---|---|---|
n anti-HBc(+)/N total per group (%) | OR | 95% CI | P-value | OR | 95% CI | P-value | ||
Age (years) | ≤ 20 | 748/1856 (40.3) | ref | ref | ||||
21–25 | 237/485 (48.9) | 1.42 | [1.2–1.7] | <0.001 | 1.5 | [1.2–2.0] | <0.001 | |
26–30 | 121/224 (54.0) | 1.74 | [1.3–2.3] | <0.001 | 2.2 | [1.5–3.2] | <0.001 | |
31–35 | 54/100 (54.0) | 1.74 | [1.2–2.6] | 0.009 | 2.0 | [1.2–3.3] | 0.006 | |
≥ 36 | 73/134 (54.5) | 1.77 | [1.2–2.5] | 0.001 | 2.3 | [1.5–3.7] | <0.001 | |
Sex | Female | 334/934 (35.8) | ref | ref | ||||
Male | 899/1865 (48.2) | 1.7 | [1.7–1.4] | <0.001 | 1.5 | [1.3–1.8] | <0.001 | |
Occupation | Student | 804/1958 (41.1) | ref | ref | ||||
Office worker | 60/189 (31.7) | 0.7 | [0.5–0.9] | 0.013 | 0.5 | [0.3–0.8] | 0.002 | |
Soldier | 226/432 (52.3) | 1.6 | [1.3–1.9] | <0.001 | 0.9 | [0.7–1.3] | 0.688 | |
Other | 143/220 (65.0) | 2.7 | [2.0–3.6] | <0.001 | 0.9 | [0.6–1.2] | 0.410 | |
Region | Centre | 241/743 (32.4) | ref | ref | ||||
South | 210/805 (26.1) | 0.7 | [0.6–0.9] | 0.006 | 0.7 | [0.6–0.9] | 0.003 | |
North | 782/1251 (62.5) | 3.5 | [2.9–4.2] | <0.001 | 3.3 | [2.6–4.0] | <0.001 |
OR = odds ratio; CI = confidence interval.
Discussion
In this study, regional, occupation, age and sex-related differences in HBV epidemiology in Lao blood donors were investigated. The seroprevalence of HBsAg extrapolated to 4982 participants was 6.9%, and was 9.2% in first-time donors after excluding repeat donors who showed a much lower proportion of HBsAg positivity (3.9%). This finding is comparable with earlier studies that found an HBsAg prevalence of 8.7% and 9.6% in first-time blood donors [15,16]. In addition, 41% of the participants were positive for anti-HBc, indicating that they had been in contact with the virus at some point during their lives. Virtually all of the donors (>99%) were born before the introduction of HBV vaccination in Lao PDR in 2001, explaining the low seroprevalence (3.5%) of anti-HBs alone profile. Since HBsAg testing was only conducted for anti-HBc positive and anti-HBs negative samples or with unknown anti-HBs status, we cannot exclude that we missed HBsAg positive samples due to false anti-HBs positives or anti-HBc negatives. For the purpose of this study, anti-HBc negative samples were considered negative for HBsAg. These samples were not tested for HBsAg, as only acute infected participants or donors with low infectivity might show this serological profile [16].
Strikingly, the rate of exposure and current infection was much higher in Northern provinces than in the Centre or South of Lao PDR, irrespective of the age group. Such regional variation has not been described before and according to our knowledge, no information about prevalence rates in neighbouring regions of the Northern provinces is available. The observed differences could relate to local variations in risk practices such as for example tattooing, piercings, birth practices and sexual exposure. Indeed, the Khmou, an ethnic group living in the North of Lao PDR, have previously been linked to increased vulnerability to prostitution and increased risk for exposure to HIV or other sexually transmitted diseases [28]. Development work in border areas, such as the improvement of route 3, linking Lao PDR to Thailand and China, has impacted the economic landscape in the Upper Mekong region. Among others, increased prevalence of HIV and rising numbers of small road side shops, often offering alcoholic beverages as well as sexual services, have been cited as negative consequences of this economic shift [28–30]. It has also been reported in other settings that the HBV and hepatitis C prevalence in indigenous populations and ethnic minorities may be higher or different than in the general population [31–36]. Follow-up studies are therefore clearly warranted and should capture potential risk factors as well as ethnicity.
Similar to previous studies [15,16], HBsAg and anti-HBc prevalence rates were higher in males than in females, both in first-time donors and in the overall cohort. The discrepancy could be related to sex-differences in the cellular immune responses to HBV infection [37,38]. This finding should be considered when designing future studies regarding disease burden and exposure.
In comparison to the youngest age group, older participants were more likely to have had an infection with HBV in the past but age did not seem to play a role in the model for being a chronic carrier. This can be explained by the fact that early age infections result more often in chronicity than infections later in life [4,5]. The positive association between age and anti-HBc seropositivity may reflect continuous exposure to hepatitis B infection in an endemic country.
In comparison to students, soldiers were more likely to be chronic carriers but they were not more likely to have had an HBV exposure. Since the high rate of HBsAg positivity indicates early life exposure, it may be hypothesized that soldiers originate more often from less wealthy families with a higher likelihood of HBV exposure than students.
Even though the rate of HBsAg positivity was significantly higher in first-time donors than in repeat donors, the fact that HBsAg positive donors return for blood donation is of concern. There are several possible explanations for this. Firstly, the detection methods used at the Lao Red Cross may not be sensitive enough to detect low levels of HBsAg. This possibility has obvious implications for blood safety and methods for the screening of blood donations should be reviewed. However, it would probably only explain a small proportion of the positive repeat donors. A second possible reason why the repeat donor HBsAg prevalence is high could be that the blood donor database may not be robust enough to exclude returning HBsAg positive donors. In another investigation we have found considerable problems with donor identification across multiple blood donation sites and counselling (manuscript in preparation). Lastly, a small number of the repeat donors may have become infected after the previous donation. Surprisingly and for unknown reasons, the prevalence of HBsAg was higher in repeat donors than in first-time donors in the province Houaphan, a finding which warrants further investigation. The higher prevalence of HBsAg in participants who donated more than 7 times compared to 4 to 6 times can be explained by low overall numbers for each blood donation group.
Serum samples from blood donors are a reasonable surrogate of the general adult population with obvious advantages concerning access and coverage of different geographical regions. A limitation of this study was that, due to financial constraints and low serum volume, not all samples could be tested for anti-HBs. However, since basically all participants were born before vaccine introduction, we do not expect the percentage of donors with post-vaccination serological profile to be much higher than among the tested participants.
Our study investigating more than 5000 blood donors from eight provinces in Lao PDR confirmed an overall high HBsAg and anti-HBc prevalence among first-time donors and for the first time reported considerable regional variations potentially linked to different risk practices. Although the study is focussed on Lao PDR, it showed that important within-country differences regarding HBV exposure may exist, which potentially require tailored public health responses. The identification of a sizeable number of HBsAg positive repeat donors warrants a thorough investigation of current blood screening, record keeping, donor identification and counselling practises to determine which steps of the blood donation process are responsible for this problem. Our findings will hopefully raise awareness also in other resource-limited settings that the monitoring of blood donation procedures may be beneficial to identify and address shortcomings regarding blood donation safety.
Supporting information
Acknowledgments
We would like to thank Mr. Did Panyathong for his technical assistance. We are grateful to Dr. Paul Brey and his administrative team for facilitating the study. We also want to thank the blood donors who agreed to participate to this study and the staff at the Lao National Blood Transfusion Center.
Data Availability
Due to ethical restrictions and participant confidentiality, the data set cannot be made publicly available. However, the data can be requested from Institut Pasteur du Laos, after obtaining permission from the National Ethics Committee for Health Research (NECHR) in the Lao PDR. The contact person for the NECHR in the Lao PDR is Dr Khampheng Phongluxa (Tel: +856-21 250670-207 and 208; Email: khampheng_p@hotmail.com; Website: http://www.laohrp.com). The Institut Pasteur du Laos can be contacted through the website (https://www.pasteur.la/contact/), by phone (Tel: +856-21 285321) or by email through Antoine des Graviers (a.desgraviers@pasteur.la).
Funding Statement
This work was supported by the Ministry of Foreign and European Affairs, Luxembourg (project “Luxembourg-Laos Partnership for Research and Capacity Building in Infectious Disease Surveillance II”) and the Luxembourg Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009;286: 9–14. doi: 10.1016/j.canlet.2008.10.040 [DOI] [PubMed] [Google Scholar]
- 2.Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4: 5–13. doi: 10.1634/theoncologist.2010-S4-05 [DOI] [PubMed] [Google Scholar]
- 3.Liu C-J, Kao J-H. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chinese Med Assoc. 2007;70: 141–145. doi: 10.1016/S1726-4901(09)70346-6 [DOI] [PubMed] [Google Scholar]
- 4.Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34: 1329–1339. doi: 10.1093/ije/dyi206 [DOI] [PubMed] [Google Scholar]
- 5.World Health Organization. Hepatitis B—Factsheet. 2020 [cited 8 May 2019]. Available: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
- 6.Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012;4: 74–80. doi: 10.4254/wjh.v4.i3.74 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30: 2212–2219. doi: 10.1016/j.vaccine.2011.12.116 [DOI] [PubMed] [Google Scholar]
- 8.Collaborators Polaris Observatory. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3: 383–403. doi: 10.1016/S2468-1253(18)30056-6 [DOI] [PubMed] [Google Scholar]
- 9.Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, et al. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. Lancet Gastroenterol Hepatol. 2016;1: 248–255. doi: 10.1016/S2468-1253(16)30031-0 [DOI] [PubMed] [Google Scholar]
- 10.Wang S, Tao Y, Tao Y, Jiang J, Yan L, Wang C, et al. Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional study. BMC Public Health. 2018;18: 1088. doi: 10.1186/s12889-018-5984-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Phoummalaysith B, Yamamoto E, Xeuatvongsa A, Louangpradith V, Keohavong B, Saw YM, et al. Factors associated with routine immunization coverage of children under one year old in Lao People’s Democratic Republic. Vaccine. 2018;36: 2666–2672. doi: 10.1016/j.vaccine.2018.03.051 [DOI] [PubMed] [Google Scholar]
- 12.Black AP, Nouanthong P, Nanthavong N, Souvannaso C, Vilivong K, Jutavijittum P, et al. Hepatitis B virus in the Lao People’s Democratic Republic: a cross sectional serosurvey in different cohorts. BMC Infect Dis. 2014;14: 457. doi: 10.1186/1471-2334-14-457 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.GAVI. Lao PDR | Gavi, the Vaccine Alliance. 2020 [cited 14 Dec 2020]. Available: https://www.gavi.org/programmes-impact/country-hub/west-pacific/lao-pdr.
- 14.World Health Organization, United Nations Children’s Fund. Lao People’s Democratic Republic: WHO and UNICEF estimates of immunization coverage: 2018 revision. 2019. [Google Scholar]
- 15.Jutavijittum P, Yousukh A, Samountry B, Samountry K, Ounavong A, Thammavong T, et al. Seroprevalence of hepatitis B and C virus infections among Lao blood donors. Southeast Asian J Trop Med Public Health. 2007;38: 674–679. Available: http://www.ncbi.nlm.nih.gov/pubmed/17883005. [PubMed] [Google Scholar]
- 16.Jutavijittum P, Andernach IE, Yousukh A, Samountry B, Samountry K, Thammavong T, et al. Occult hepatitis B infections among blood donors in Lao PDR. Vox Sang. 2014;106: 31–37. doi: 10.1111/vox.12073 [DOI] [PubMed] [Google Scholar]
- 17.Komada K, Sugiyama M, Vongphrachanh P, Xeuatvongsa A, Khamphaphongphane B, Kitamura T, et al. Seroprevalence of chronic hepatitis B, as determined from dried blood spots, among children and their mothers in central Lao People’s Democratic Republic: a multistage, stratified cluster sampling survey. Int J Infect Dis. 2015;36: 21–26. doi: 10.1016/j.ijid.2015.04.020 [DOI] [PubMed] [Google Scholar]
- 18.Xeuatvongsa A, Komada K, Kitamura T, Vongphrachanh P, Pathammavong C, Phounphenghak K, et al. Chronic hepatitis B prevalence among children and mothers: results from a nationwide, population-based survey in Lao People’s Democratic Republic. PLoS One. 2014;9: e88829. doi: 10.1371/journal.pone.0088829 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Norizuki M, Kitamura T, Komada K, Sugiyama M, Mizokami M, Xeuatvongsa A, et al. Serologic testing of randomly selected children after hepatitis B vaccination: A cross-sectional population-based study in Lao People’s Democratic Republic. BMC Infect Dis. 2019;19: 1–9. doi: 10.1186/s12879-018-3567-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Evdokimov K, Sayasinh K, Nouanthong P, Vilivong K, Samountry B, Phonekeo D, et al. Low and disparate seroprotection after pentavalent childhood vaccination in the Lao People’s Democratic Republic: a cross-sectional study. Clin Microbiol Infect. 2017;23: 197–202. doi: 10.1016/j.cmi.2016.10.007 [DOI] [PubMed] [Google Scholar]
- 21.World Health Organization. Screening donated blood for transfusion-transmissible infections: recommendations. 2010. Available: https://www.who.int/bloodsafety/ScreeningDonatedBloodforTransfusion.pdf. [PubMed] [Google Scholar]
- 22.R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, Vienna, Austria; 2019. Available: https://www.r-project.org/. [Google Scholar]
- 23.Wickham H. tidyverse: easily install and load the “Tidyverse.” 2017. Available: https://cran.r-project.org/package=tidyverse. [Google Scholar]
- 24.Venables WN, Ripley BD. Modern Applied Statistics with S. Fourth. New York: Springer US; 2002. Available: http://www.stats.ox.ac.uk/pub/MASS4. [Google Scholar]
- 25.Fox J, Weisberg S, Fox J. An R companion to applied regression. 2010. Available: https://books.google.la/books/about/An_R_Companion_to_Applied_Regression.html?id=YH6NotdvzF0C&redir_esc=y. [Google Scholar]
- 26.Zeileis A, Hothorn T. Diagnostic checking in regression relationships. R News. 2: 7–10. [Google Scholar]
- 27.Aragon Tomas J. epitools: epidemiology tools. 2017. Available: https://cran.r-project.org/package=epitools. [Google Scholar]
- 28.Lyttleton C, Vorabouth S. Culture, Health & Sexuality: An international journal for research, intervention and care trade circles: aspirations and ethnicity in commercial sex in Laos.: 37–41. doi: 10.1080/13691058.2011.562307 [DOI] [PubMed] [Google Scholar]
- 29.Lyttleton C. Build it and they will come—lessons from the northern economic corridor: mitigating HIV and other diseases. 2009; 38pp. doi: 978-971-561-864-9 [Google Scholar]
- 30.Doussantousse S, Sakounnavong B, Patterson I. An expanding sexual economy along National Route 3 in Luang Namtha Province, Lao PDR. Cult Heal Sex. 2011;13: 37–41. doi: 10.1080/13691058.2011.584633 [DOI] [PubMed] [Google Scholar]
- 31.World Health Organization. Global hepatitis report, 2017. 2017. [Google Scholar]
- 32.Hipgrave DB, Nguyen T Van, Vu MH, Hoang TL, Do TD, Tran NT, et al. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization. Am J Trop Med Hyg. 2003;69: 288–294. [PubMed] [Google Scholar]
- 33.Murhekar M V, Murhekar KM, Sehgal SC. Epidemiology of hepatitis B virus infection among the tribes of Andaman and Nicobar Islands, India. Trans R Soc Trop Med Hyg. 2008;102: 729–734. doi: 10.1016/j.trstmh.2008.04.044 [DOI] [PubMed] [Google Scholar]
- 34.Seroprevalence Apidechkul T. and factors associated with hepatitis B virus infection among the hill tribe youths, northern Thailand. BMC Infect Dis. 2019;19: 1–11. doi: 10.1186/s12879-018-3567-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Ishida T, Takao S, Settheetham-Ishida W, Tiwawech D. Prevalence of hepatitis B and C virus infection in rural ethnic populations of Northern Thailand. J Clin Virol. 2002;24: 31–35. doi: 10.1016/s1386-6532(01)00222-0 [DOI] [PubMed] [Google Scholar]
- 36.Shen YY, Hou W, Yang ZQ, Xiao W. Hepatitis B virus infection and genotype in asymptomatic people from 10 ethnic groups in Yunnan, China. World J Gastroenterol. 2015;21: 12586–12592. doi: 10.3748/wjg.v21.i44.12586 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent outcome of hepatitis B and C Viruses infections: Synergy of sex hormones and immune responses? Front Immunol. 2018;9: 1–7. doi: 10.3389/fimmu.2018.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Van Lunzen J, Altfeld M. Sex differences in infectious diseases-common but neglected. J Infect Dis. 2014;209: 79–80. doi: 10.1093/infdis/jiu159 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Due to ethical restrictions and participant confidentiality, the data set cannot be made publicly available. However, the data can be requested from Institut Pasteur du Laos, after obtaining permission from the National Ethics Committee for Health Research (NECHR) in the Lao PDR. The contact person for the NECHR in the Lao PDR is Dr Khampheng Phongluxa (Tel: +856-21 250670-207 and 208; Email: khampheng_p@hotmail.com; Website: http://www.laohrp.com). The Institut Pasteur du Laos can be contacted through the website (https://www.pasteur.la/contact/), by phone (Tel: +856-21 285321) or by email through Antoine des Graviers (a.desgraviers@pasteur.la).